Pharvaris (NASDAQ:PHVS) Shares Up 5.5% – Here’s Why

Pharvaris (NASDAQ:PHVS) shares were up 5.5% during trading on Friday . The company traded as high as $15.79 and last traded at $16.32. Approximately 4,433 shares changed hands during mid-day trading, a decline of 94% from the average daily volume of 70,040 shares. The stock had previously closed at $15.46.

Analyst Ratings Changes

Separately, JMP Securities increased their price objective on Pharvaris from $46.00 to $55.00 and gave the company a “market outperform” rating in a report on Friday, January 31st.

Pharvaris Trading Down 0.4 %

The business has a 50 day moving average of $16.87 and a 200-day moving average of $19.05. The stock has a market cap of $805.27 million, a PE ratio of -5.50 and a beta of -3.02.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. FMR LLC grew its stake in Pharvaris by 3.6% during the 4th quarter. FMR LLC now owns 5,395,370 shares of the company’s stock worth $103,429,000 after buying an additional 189,714 shares during the last quarter. Soleus Capital Management L.P. grew its stake in shares of Pharvaris by 36.2% in the 4th quarter. Soleus Capital Management L.P. now owns 814,652 shares of the company’s stock valued at $15,617,000 after purchasing an additional 216,483 shares during the last quarter. Octagon Capital Advisors LP grew its stake in shares of Pharvaris by 25.4% in the 4th quarter. Octagon Capital Advisors LP now owns 778,000 shares of the company’s stock valued at $14,914,000 after purchasing an additional 157,530 shares during the last quarter. Rock Springs Capital Management LP grew its stake in shares of Pharvaris by 2.4% in the 4th quarter. Rock Springs Capital Management LP now owns 775,131 shares of the company’s stock valued at $14,859,000 after purchasing an additional 18,200 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Pharvaris by 36.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 443,896 shares of the company’s stock valued at $8,510,000 after purchasing an additional 118,408 shares during the last quarter.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.